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Recently, a number of reports have shown that neurogenic inflammation may play a role in the 
secondary injury response following acute injury to the central nervous system (CNS), 
including traumatic brain injury (TBI) and stroke. In particular substance P (SP) release appears 
to be critically involved. Specifically, expression of the neuropeptide SP is increased in acute 
CNS injury, with the magnitude of SP release being related to both the frequency and 
magnitude of the insult. SP release is associated with an increase in blood-brain barrier 
permeability and the development of vasogenic oedema as well as neuronal injury and 
worsened functional outcome. Moreover, inhibiting the actions of SP through use of a NK1 
antagonist is highly beneficial in both focal and diffuse models of TBI, as well as in ischaemic 
stroke, with a therapeutic window of up to 12h. We propose that NK1 antagonists represent a 
novel therapeutic option for treatment of neurogenic inflammation following acute CNS injury.  
 
 
Keywords: ischaemic stroke, neurogenic inflammation, NK1 antagonist, substance P, 
traumatic brain injury 
 
Abbreviations:  blood brain barrier    BBB   
IL     interleukin 
intracranial pressure    ICP   
middle cerebral artery   MCA   
n-acetyl-L-tryptophan   NAT   
n-methyl-D-aspartate    NMDA  
reactive oxygen species   ROS   
SEM     standard error of the mean 
substance P     SP   
traumatic brain injury   TBI   
tumour necrosis factor   TNF   
tissue plasminogen activator   tPA   
 
Experiments: All animal experiments were approved by the local institutional ethics 
committee and conducted according to the National Health and Medical Council (Australia) 
guidelines for the use of laboratory animals in experimental research. All animal care and 
experimental procedures were in accordance with the ARRIVE guidelines   
 3 
Acute insults to the CNS, such as traumatic brain injury (TBI) and ischaemic stroke, are a major 
cause of morbidity and mortality today representing a significant public health issue 
worldwide. An estimated 10 million people are affected annually by a TBI serious enough to 
result in death or hospitalisation, with a mortality rate of 15-30 per 100,000 reported in 
industrialised countries (Finfer et al., 2001; Tagliaferri et al., 2006). Stroke affects some 15 
million individuals worldwide each year, of which 1/3 die and 1/3 are left permanently disabled 
and dependent for daily living (World Health Organisation, 2004).  
 
In both TBI and ischaemic stroke, cell death is caused by both primary (the initial insult) and 
secondary injury mechanisms. Whilst the nature of primary injury differs between TBI and 
ischaemic stroke, the secondary injury cascade shares many similarities, with inflammation, 
and more recently neurogenic inflammation, shown to be key determinants of neuronal injury 
and functional outcome in both conditions. The current article provides data supporting a 
critical role for neurogenic inflammation, and particularly substance P (SP) release, in the 
secondary injury response following TBI and ischaemic stroke, and discusses this data in the 
context of previously published reports. 
 
Traumatic Brain Injury 
TBI results from the head impacting with an object or from acceleration/deceleration forces 
that produce vigorous movement of the brain within the skull, with the resultant mechanical 
forces potentially damaging glia, neurones, axons and blood vessels. The type and severity of 
the injury depends upon the nature of the initiating force, as well as its site, direction and 
magnitude (Smith et al., 2003). Contact forces generated when the head strikes or is struck by 
an object generally produce focal injuries such as skull fractures, extradural haemorrhages, and 
contusions. In contrast, acceleration/deceleration forces that result from violent unrestrained 
head movement are associated with diffuse axonal injury (Blumbergs et al., 2008).  Focal 
injuries, such as contusions lead to the development of an area of dead tissue (the necrotic core) 
which is surrounded by a penumbral area. This area is known to also undergo ischaemia, due 
to haemorrhage, disruptions in venous drainage and vasoconstriction, and this contributes 
which contributes to the secondary injury process in this region (Leker et al., 2002).  
 
Ischaemic Stroke 
In ischaemic stroke, the primary injury is the sudden and profound reduction of blood flow to 
an area of the brain, most commonly because of atherothrombosis of cerebral vessels or emboli 
(Hademenos et al., 1997). The amount of cell death is dependent upon the severity and duration 
of the resultant ischaemia, in addition to the availability of collateral blood supply. The ensuing 
infarct may be divided into two regions, the core and the penumbra. Within the core of the 
infarct, blood flow falls to less than 20% causing rapid cell death due to insufficient supply of 
substrate to maintain cellular energy production. The ischaemic penumbra surrounding the core 
is an area of reduced perfusion in which cells are still viable. Their survival is only possible for 
a limited time, due to the initiation of a number of pathological processes, that are similar to 
that seen following TBI. (Bouts et al., 2013).  
 
Secondary Injury 
As outlined above TBI, results primarily from a mechanical impact which disrupts the brain 
parenchyma and causes shearing and tearing of blood vessels and axons (Bramlett et al., 2004). 
In contrast in ischaemic stroke a cessation of blood supply leads to cellular death due to a 
deprivation of oxygen and glucose (Leker et al., 2002).   Despite the disparity in these primary 
injury mechanisms, they both lead to the activation of molecular and cellular response that lead 
to secondary injury, with similarities noted in the harmful pathways that lead to secondary cell 
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death in the penumbral ischaemic zone and in the area exposed to secondary post-traumatic 
brain injury.  These include an increase in extracellular levels of glutamate, leading to 
excitotoxicity, the onset of oxidative stress, disruption to the blood-brain barrier (BBB), 
cerebral oedema formation,  and inflammation (Fig. 1), all of which exacerbate injury and 
tissue damage (Saatman et al., 1996). Of particular interest is the role that inflammation can 
play in this secondary injury cascade and whether modification of this inflammatory process 
has the potential to improve outcome.  
 
Inflammation 
A marked inflammatory reaction accompanies any acute insult to the CNS, including ischaemic 
stroke and TBI (Danton et al., 2003). In the immediate phase following the initial insult this 
inflammatory response exacerbates cell injury and worsens outcome. Briefly, such an 
inflammatory response is characterised by glial activation, proliferation of microglia, leukocyte 
recruitment and upregulation and secretion of mediators such as cytokines and chemokines 
(Ziebell et al., 2010). Microglial cells become activated and release a variety of neurotoxic 
factors including pro-inflammatory cytokines, reactive oxygen species (ROS), nitric oxide and 
metalloproteinases (Brown et al., 2010). Cytokines like interleukin-1 (IL-1) play a key role 
orchestrating the release of other neurotoxic mediators such as ROS, proteases and 
prostaglandins, whilst tumour necrosis factor (TNF) promotes the release of proteolytic 
enzymes, breakdown of the BBB and induction of cell death (Shohami et al., 1999). Whilst the 
role of the classical inflammatory response has been well characterised (Danton et al., 2003; 
Morganti-Kossmann et al., 2002), the important role that neurogenic inflammation plays in 
exacerbating the secondary injury cascade has only recently begun to be recognised.  
 
Neurogenic Inflammation 
Neurogenic inflammation is a neurally-elicited inflammatory response characterised by the 
release of neuropeptides, including SP and calcitonin gene-related peptide (CGRP), 
vasodilation, plasma extravasation, tissue swelling and mast cell degranulation (Severini et al., 
2002). It results from the stimulation of capsaicin-sensitive, neuronal C fibres by factors such 
as serotonin, histamine and leukotrienes, as well as by changes in pH, extremes of temperature 
and by mechanical injury (Harrison et al., 2001; Saria et al., 1983). 
 
Substance P 
SP is thought to be the most potent initiator of neurogenic inflammation due to its association 
with increased vascular permeability and subsequent plasma protein extravasation (Holzer, 
1998). It also potentiates classical inflammation by stimulating the production of inflammatory 
mediators such as histamine, nitric oxide, cytokines (such as IL-6) and kinins, in addition to 
interacting with adhesion molecules causing leukocyte migration (Averbeck et al., 2001).  
 
SP is a member of the tachykinin family, a group of structurally related peptides sharing the 
same carboxyl terminal sequence which also includes neurokinin A and neurokinin B (Schaffer 
et al., 1998). It is derived from the preprotachykinin-A (PPT-A) gene, which is spliced to form 
four different mRNA forms, namely α-PPT, β-PPT, γ- PPT and δ-PPT (Harrison et al., 2001). 
The α-PPT and β-PPT forms encode for SP alone whilst the γ- PPT and δ-PPT encode for both 
SP and neurokinin A (Severini et al., 2002). The α-PPT is more abundant within the brain, 
whilst the β-PPT form is found primarily within the peripheral nervous system (PNS) (Ribeiro-
da-Silva et al., 2000). Indeed, SP is widely distributed throughout the CNS, PNS and enteric 
nervous systems. In the CNS it is present in dorsal root ganglion (primary sensory) neurons 
(Hokfelt et al., 2001) of many regions including the hippocampus, cortex, basal ganglia, 
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hypothalamus, amygdala, caudate nucleus and spinal cord, and seems to be more abundant in 
the grey matter compared to white matter (Ebner et al., 2006).  
 
SP is synthesized in the ribosome as a large protein and transported to the terminal endings, 
where it is enzymatically converted into the active form and stored in vesicles ready for release 
(Lundy et al., 2004). Its actions are primarily mediated through the tachykinin NK1 receptor 
to which it preferentially binds, although it also binds to the other tachykinin receptors, NK2 
and NK3, with varying affinity depending upon receptor and ligand availability (Regoli et al., 
1994). The NK1 receptor is a typical G-protein coupled receptor with seven transmembrane 
domains (Garland et al., 1994) and is found on neurons and glia in the CNS, smooth muscle 
cells, endothelial cells, fibroblasts, keratinocytes and various circulating immune and 
inflammatory cells (Schaffer et al., 1998). On unstimulated neurons, NK1 receptors are 
localised to the plasma membrane of both the cell body and dendrites, but following SP 
binding, they are rapidly internalised into the cytoplasm via endosomes (Mantyh, 2002). This 
internalisation is readily reversible with complete return of internalised receptors to the surface 
within 30 minutes.  
 
The intracellular signalling pathways activated by the NK1 receptor appear to be cell-
dependent. In endothelial cells, SP binding to the NK1 receptor promotes phosphorylation of 
myosin by myosin light chain kinase (MLCK) which in turn promotes the interaction of actin 
and myosin, leading to cell retraction and the formation of gaps between endothelial cells 
(Holzer, 1998; van Hinsbergh et al., 2002). In contrast, in vascular smooth muscle, the 
vasodilatory actions of SP involve activation of adenylate cyclase producing cAMP, which 
activates calcium ATPases, reducing intracellular calcium levels and promoting relaxation and 
dilation of vascular smooth muscle (Maggi, 1995). In other cell types, such as astrocytes and 
microglia, binding of SP to the NK1 receptor leads to activation of phospholipase C, which 
catalyses the hydrolysis of phosphoinositides into inositol 1,4,5-trisphosphate and 
diacylglycerol, which then allow mobilisation of calcium from internal stores (O'Connor et al., 
2004). This increase in calcium levels within primary afferents is thought to be involved in the 
decrease of the threshold for signalling of nociceptive information following injection of SP 
into the skin.  
 
The role of SP following TBI 
Previous research in our laboratory has found that SP plays an integral role in the secondary 
injury cascade following TBI (Donkin et al., 2009; Nimmo et al., 2004). Following diffuse TBI 
in rats, an increase in SP immunoreactivity is noted at both 5 and 24h following injury, with a 
gradual return to sham levels by 7 days post-injury (Donkin et al., 2009). Consistent with the 
animal studies, in human TBI, postmortem SP immunoreactivity was increased perivascularly 
as well as in cortical neurones and astrocytes in the majority of cases examined (Zacest et al., 
2010). This release of SP appears to be both intensity and frequency dependent, with a graded 
increase in SP immunoreactivity seen with increasing severity of injury. Consistent with this, 
experimental studies conducted in our laboratory (Fig. 2) show that the highest level of SP 
immunoreactivity is observed following a 2m (severe) impact TBI, whilst a 0.5m (mild) impact 
TBI causes only a minimal increase in SP immunoreactivity. Increased axonal injury and 
worsening of motor outcome is also observed as the severity of injury increases (Marmarou et 
al., 1994), suggesting that SP may play a role in the heightened secondary injury response with 
increased injury severity. Notably, we have previously shown that axonal injury is reduced and 
functional outcome improved with administration of an NK1 antagonist (Donkin et al., 2011). 
Previous studies examining SP release following thermal stimuli have also shown that stepwise 
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increases at the extremes of temperature (<10°C and >43°C) results in a graduated release of 
SP and associated internalisation of the NK1 receptors (Allen et al., 1997).  
 
Repeated exposure to a stimulus has also been shown to cause increased SP release and greater 
activation of NK1 receptor expressing cells (Mantyh, 2002), with diffusion of SP away from 
the site of release causing more widespread activation, estimated to be 3-5 times that of a single 
exposure. The brain is known to be more vulnerable to repeated injury, with rodents 
demonstrating prolonged cognitive deficits and enhanced axonal injury not seen with a single 
impact (Longhi et al., 2005). This suggests that enhanced release of SP may potentially play a 
role in the vulnerability of the brain to repeated concussions. 
 
Antagonism of SP following TBI 
The important role that SP plays in the secondary injury process following TBI has been 
confirmed in a number of studies that have shown that attenuating SP activity is beneficial to 
outcome (Vink et al., 2010). The first demonstration of neurogenic inflammation in TBI 
showed that depletion of sensory neuropeptides by pre-treatment with capsaicin results in the 
attenuation of post-traumatic BBB permeability, oedema formation and improved functional 
outcome (Nimmo et al., 2004). While not identifying the sensory neuropeptide responsible for 
these post-traumatic effects, subsequent studies identified increased SP immunoreactivity as a 
possible therapeutic target. Accordingly treatment with an NK1 antagonist, targeting SP 
binding, was utilised after TBI in both male (Donkin et al., 2009) and female rats (Corrigan et 
al., 2012) which led to a significant attenuation of post-traumatic blood-brain barrier (BBB) 
permeability with a significant reduction in oedema formation. This was accompanied by a 
reduction in axonal injury and associated improvement in both motor and cognitive outcome. 
Further evidence supporting a role for SP in TBI was provided in studies that administered an 
angiotensin converting enzyme (ACE) inhibitor, which inhibits the breakdown of SP. 
Following ACE inhibitor administration, levels of SP were significantly increased after TBI, 
exacerbating neuronal injury and motor deficits (Harford-Wright et al., 2010). In terms of the 
therapeutic window for neuroprotective action, treatment up to 12h post-injury with a centrally 
acting NK1 antagonist was still able to provide significant benefit, with marked improvements 
noted in motor performance (Donkin et al., 2011). 
 
All of the initial TBI studies characterising neurogenic inflammation utilised the Marmarou 
impact-acceleration model of TBI, which causes diffuse injury with widespread axonal 
damage, particularly in the long tracts of the brain stem, as well as within the corpus callosum 
and internal capsule (Marmarou et al., 1994). As human TBI covers the spectrum from diffuse 
through to focal injury, it is important to determine whether therapies targeting SP are equally 
efficacious in both types of injury. The fluid percussion model of TBI utilises the application 
of a rapid pressure pulse onto the exposed and intact dura to cause a brief displacement and 
focal deformation of the brain tissue (Corrigan et al., 2011). This produces primarily a focal 
contusion, accompanied by axonal injury in the fimbria and internal capsule (Thompson et al., 
2005). It is thus a highly suitable model to examine the effects of NK1 antagonists on focal 
TBI. Figure 3 demonstrates that administration of an NK1 antagonist, n-acetyl-L-tryptophan 
(NAT; 2.5 mg/kg iv) at 30 mins post-injury following fluid percussion induced TBI led to a 
similar significant improvement in motor outcome on the rotarod as that seen previously 
following diffuse injury. Specifically, NAT treated rats performed significantly better (p<0.05) 
than saline vehicle treated rats on days 1, 2, 4 and 5 post-injury, and had in fact returned to 
sham levels by day 4, whilst the vehicle treated rats still showed significant motor deficits on 
day 7, the final day of testing. Thus, administration of an NK1 antagonist significantly 
improved outcome after TBI, irrespective of the focal or diffuse nature of the injury. 
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While the role of neurogenic inflammation had been confirmed in both focal and diffuse TBI, 
and the NK1 antagonist had proven efficacious in both male and female animals, all 
pharmacological studies had been limited to rodents, which have historically led to few 
successful therapeutic translations to the clinic, particularly in the area of acute CNS injury. To 
increase the likelihood of successful clinical translation, it is important to test therapeutics 
developed in rodent models in large animal models given the anatomical differences between 
the small lissencephalic rodent brain and the larger gyrencephalic human brain. This has been 
a particular focus of our laboratory in recent years, which has developed models of both TBI 
and stroke in sheep (Finnie et al., 2012; Van Den Heuvel et al., 2004; Wells et al., 2012). As 
with the rodent studies, sheep demonstrated an increased SP immunoreactivity after TBI 
associated with increased BBB permeability and marked oedema formation, as well as 
significant increases in intracranial pressure (ICP) that were associated with brain water 
accumulation (Byard et al., 2009). Administration of an NK1 antagonist in this sheep TBI 
model was able to significantly reduce ICP levels to normal within 4 h of drug administration 
as compared to the sustained elevation in ICP in the vehicle-treated sheep (Gabrielian et al., 
2013). This reduction in ICP is consistent with the ability of the NK1 antagonists to consistently 
reduce brain water concentration to normal levels in the previously published rodent studies 
(Vink et al., 2010).  
 
The role of SP following ischaemic stroke 
We have described above that neurogenic inflammation involving SP release is a ubiquitous 
feature of TBI, regardless of whether the insult is mild, moderate or severe or whether it is 
diffuse or focal in nature (see Fig. 2). Many of the secondary injury pathways that feature in 
TBI also significantly contribute to the development of infarction following stroke. Indeed, we 
have reported a significant SP response in ischaemic tissue following experimental stroke in 
rodents (Turner et al., 2006). However, in the setting of cerebral ischaemia, it appears that SP 
release may not be as ubiquitous a feature of stroke as it is in TBI, and may be dependent upon 
the reperfusion status of the tissue.  
 
SP immunoreactivity is particularly evident in the perivascular tissue of the ischaemic 
penumbra, as well as in neuronal and glial cells within this region (Turner et al., 2006; Turner 
et al., 2011). Levels of SP in the penumbra gradually increase with time following reperfusion, 
reaching a nadir at 24 h post-reperfusion (Turner et al., 2011). In contrast, the core of the stroke 
lesion does not demonstrate appreciable SP immunoreactivity. Thus, there appears to be a 
difference in the SP response that is dependent upon the perfusion status of the tissue. To 
further demonstrate this effect, our laboratory has shown in rodents that 24h of permanent 
middle cerebral artery (MCA) occlusion results in only modest elevations in SP 
immunoreactivity beyond sham levels. In contrast, 2h of transient MCA occlusion followed by 
22h reperfusion is associated with profound increases in perivascular SP immunoreactivity 
within the penumbral tissue. These alterations in SP levels were confirmed using ELISA assays 
of the ischaemic hemisphere (Turner et al., 2011). The results suggest that in regions where 
infarction has occurred, there is no SP response, whereas in the surrounding surviving but 
compromised penumbral tissue, SP is playing a role in the development of secondary injury. 
We posit that SP release may be a feature of reperfusion injury and that neurogenic 
inflammation may contribute to and exacerbate injury to the brain following stroke. It must be 
acknowledged that these findings may be model and species dependent. However, no data 
describing a difference in the SP response exists to date for other experimental models of stroke 
or in clinical samples.  
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Following transient ischaemia, SP immunoreactivity is maximal at 24h following stroke, and 
declines thereafter over the next 7d. Increased BBB permeability has been reported at various 
time-points following stroke, and the 24 h time-point when SP was markedly increased in our 
studies is consistent with such reports (Preston et al., 1993). Indeed, the 24h time point in our 
stroke model was associated with profound disruption of the BBB (Turner et al., 2006), 
together with development of cerebral oedema and persistent functional deficits (Turner et al., 
2011). SP therefore offers an attractive pharmacological target to reduce BBB permeability and 
the development of oedema following transient ischaemia. 
 
Antagonism of SP following ischaemic stroke 
A number of studies have now demonstrated that inhibition of neurogenic inflammation, and 
in particular SP activity, significantly improves outcome following transient ischaemia. In a 
rodent model of transient MCA occlusion, administration of the NK1 receptor antagonist NAT 
at 4 h post-occlusion significantly attenuated BBB permeability and in turn completely 
ameliorated cerebral oedema and improved functional outcome (Turner et al., 2011). 
Moreover, NK1 antagonists can be safely combined with thrombolysis (Turner et al., 2012b), 
which is of particular importance given the integral role that thrombolysis plays in clinical 
stroke management (Medcalf et al., 2012). Specifically, combination treatment of tissue 
plasminogen activator (tPA; alteplase) with NAT significantly improved BBB function as well 
as functional outcome, and importantly reduced the incidence of intracerebral haemorrhage 
associated with tPA administration. Presumably, the NK1 antagonist prevented vascular 
disruption induced by tPA by maintaining the integrity of the BBB. 
 
In terms of the therapeutic window, studies of transient (2h) MCA occlusion in rats conducted 
in our laboratory (Fig. 4) have demonstrated that an NK1 antagonist (NAT; 25µmoles/kg iv) 
can be administered up to 8h following the onset of stroke and still result in a significant 
improvement in rotarod motor function, and up to 12h following stroke onset with a significant 
improvement in sensory function (bilateral asymmetry). Moreover, the treatment at 8h was 
effective irrespective of the period of MCA occlusion (Fig. 5), thus demonstrating efficacy 
over a range of mild to severe stroke. The 8-12 h therapeutic window is both highly relevant 
and achievable, especially when considered against the 4.5h window of opportunity currently 
considered safe for clinical thrombolysis with tPA (Medcalf et al., 2012). Notably, a 
comparable therapeutic window of 12h exists for the administration of NK1 antagonists in TBI 
(Donkin et al., 2011).  
 
The role of SP in the secondary injury response 
The exact mechanisms by which SP influences outcome following TBI and stroke are yet to be 
fully characterised, although the neuropeptide is known to influence a number of secondary 
injury factors that have been well described following acute CNS injury, including classical 
inflammation, BBB breakdown, excitotoxicity and magnesium homeostasis (Vink et al., 2010). 
 
Classical inflammation 
It is widely accepted that treatments that limit the inflammatory response during the acute phase 
of experimental CNS injury have beneficial effects on outcome, and considerable effort has 
been directed at developing more effective anti-inflammatory approaches (Nimmo et al., 
2009). In this respect, the effect of SP on classical inflammation is highly relevant and is one 
mechanism by which NK1 antagonists may ameliorate secondary injury and improve outcome. 
SP induces and augments many aspects of the classical inflammatory response including 
leukocyte activation, endothelial cell adhesion molecule expression, cytokine production and 
mast cell activation (Quinlan et al., 1999). SP also promotes secretion of cytokines including 
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IL-1, IL-6, IL-12 and TNF- by cells of the myeloid lineage, interferon-γ (IFN-y) by T cells 
and down-regulates anti-inflammatory cytokines such as transforming growth factor-β (TGF-
β) (Marriott et al., 2001; McCormack et al., 1996). Following activation of NK1 receptors on 
endothelial cells, adhesion molecules are rapidly mobilised to the surface (Zimmerman et al., 
1992), with SP exerting direct chemotactic actions on neutrophils (Carolan et al., 1993) and 
also priming them for oxidative metabolism, increasing the production of free radicals 
(Hafstrom et al., 1989). Astrocytes also express NK1 receptors following injury, and their 
activation is thought to contribute to the transformation to reactive astrocytes, with the resultant 
production of inflammatory mediators (Lin, 1995). Following TBI, NK1 antagonists have been 
shown to significantly reduce production of the pro-inflammatory cytokine IL-6 (Reardon et 
al., 2004) as well as to decrease microglial proliferation (Carthew et al., 2012). Similar 
reductions in IL-6 as well as TNF- have also been reported in a mouse model of bacterial 
meningitis in response to administration of an NK1 antagonist (Chauhan et al., 2008). 
 
Effects of SP on the BBB 
The BBB is a highly selective barrier formed by a monolayer of endothelial cells that are joined 
together by tight junctions including proteins such as claudins, occludin, junctional adhesion 
molecules (JAMs) and zonula occludens proteins (ZOs) (Huber et al., 2001). This endothelial 
layer is supported by the end-feet of astrocytes that act to support and enhance the tight 
junctions. Any increase in the permeability of the BBB following acute CNS injury permits the 
extravasation of proteins and solutes from the cerebral vasculature into the extracellular space 
within the brain, leading to a net movement of water in the same direction and a subsequent 
increase in brain volume (Kimelberg, 1995). Due to the limited capacity of the skull to 
accommodate excess fluid, this increase in volume with the entry of water has deleterious 
consequences, including an increase in ICP. Such an increase in ICP inevitably decreases 
cerebral perfusion pressure (CPP) and can ultimately lead to brain herniation and its associated 
adverse events including localised ischemia and even cessation of respiration. The formation 
of cerebral oedema is thus a major cause of clinical deterioration, being associated with 
increased mortality and morbidity following TBI (Rhine et al., 2012) and the leading cause of 
death within the first week of an ischaemic stroke (Hacke et al., 1996). 
 
SP is known to promote increased permeability of the BBB leading to increased extravasation 
of vascular protein into the brain extracellular space, both via transcellular and paracellular 
mechanisms. Indeed, previous studies have shown that intravenous injection of SP increases 
the permeability of dural blood vessels, with widening of the junctions between endothelial 
cells (Ghabriel et al., 1999). It also has effects on tight junction proteins, with decreased levels 
of ZO-1 and claudin 5 reported in cerebral capillary endothelial cells upon application of SP 
(Lu et al., 2008). Not only does SP directly increase the permeability of the BBB, but it also 
leads to upregulation of adhesion molecules and MHC class II antigens leading to recruitment 
and migration of inflammatory cells across the BBB, thereby potentiating the inflammatory 
response and exacerbating tissue injury (Annunziata et al., 2002). The ability of SP to activate 
microglia and astrocytes also contributes to the increased permeability of the BBB. Increased 
permeability of the BBB has been repeatedly demonstrated following acute brain injury, and 
notably, administration of an NK1 antagonist significantly attenuates the BBB permeability 
back to normal levels, as measured by Evan’s blue extravasation, in both TBI (Donkin et al., 
2009) and stroke (Turner et al., 2011; Turner et al., 2013). This reduction in BBB permeability 




Levels of extracellular glutamate profoundly increase immediately after both TBI and stroke 
(Bullock et al., 1998; Hazell, 2007) leading to excitotoxic cell death through increased calcium 
flux into neurons. The increase in extracellular glutamate is due to uncontrolled release of the 
excitatory amino acid with neuronal depolarisation, as well as a decrease in its reuptake caused 
by impaired glutamate transporter activity (Yi et al., 2006) and a reduction in the numbers of 
astrocytic glutamate transporters (van Landeghem et al., 2006). Accumulation of intracellular 
calcium activates a number of calcium-dependent enzymes including proteases, lipases, 
translocases and endonucleases which degrade cellular structures and eventually cause 
neuronal degeneration (Maas et al., 2008).  
 
SP and glutamate have been shown to be co-localised within the dorsal horn (Battaglia et al., 
1988; Merighi et al., 1991), parts of the brainstem (Liu et al., 2004)(Guiard et al., 2007) and 
striatum (Penny et al., 1986). Previous research has indicated a bi-directional relationship with 
glutamate able to stimulate release of SP via activation of pre-synaptically located NMDA 
receptors (Liu et al., 1997), whilst SP also facilitates glutamate release (Guiard et al., 
2007)(Kangrga et al., 1990), through a NK1 receptor dependent fashion, most likely through 
mobilisation of intracellular calcium stores (Stacey et al., 2002). Indeed, in an organotypic 
brain slice culture model, application of substance P, as well as another specific NK1 receptor 
agonist, septide, stimulated glutamate release leading to an increase in spontaneous excitatory 
synaptic currents (Stacey et al., 2002).  SP can also alter the activity of n-methyl-D-aspartate 
(NMDA) receptors, which are primarily responsible for calcium influx following the binding 
of glutamate.  Pre-application of SP led to a sustained potentiation of the current mediated by 
NMDA receptors in cultured rat dorsal root ganglion neurons, an effect that could be reversed 
with application of an NK1 antagonist (Wu et al., 2004) (Castillo et al., 2011). A potential 
mechanism was suggested to involve NK1 receptor activation induced hydrolysis of 
phosphoionsitide to diacylglycerol leading to the activation of PKC (Castillo et al., 2011). PKC 
is known to produce a positive phosphorylation modulation of the NMDA receptor, enhancing 
its activity (Lan et al., 2001). These studies support a SP-NK1 role in the release of glutamate 
and the activity of the NMDA receptor, but the direct effects of NK1 antagonism on measures 
of excitotoxicity following TBI or stroke have yet to be examined. 
 
Magnesium 
Acute insults to the CNS decrease levels of free magnesium both within the brain and the blood, 
with the magnitude of the decline linked to the severity of the injury as assessed by functional 
outcome (Heath et al., 1999; Turner et al., 2012a). This is consistent with the critical role that 
optimal magnesium concentration plays in diverse biological processes including energy 
transduction, phosphorylation reactions, protein synthesis, DNA synthesis, preservation of 
membrane integrity, maintenance of ionic gradients, and in regulation of calcium transport and 
accumulation. The ion also has a gating function with respect to the NMDA receptor, with low 
concentrations of intracellular magnesium potentiating NMDA receptor activity and calcium 
entry. A decline in magnesium post-injury has therefore been associated with exacerbation of 
other secondary injury pathways such as excitotoxicity, mitochondrial dysfunction, apoptosis, 
bioenergetics failure and oxidative stress (Turner et al., 2012a). Critically, administration of an 
NK1 antagonist after TBI is able to reverse this decline in magnesium with treated rats 
demonstrating normal magnesium levels (Vink et al., 2004), with associated improvement in 
histological and functional outcome. The exact mechanism whereby SP promotes normal 
magnesium homeostasis is yet to be determined, with the possibility that restored magnesium 
levels simply reflect improved neuronal function. However, there may also be a direct 
relationship between SP and magnesium given that magnesium deficiency is associated with 
 11 
elevations in the plasma concentrations of SP (Weglicki et al., 1992) and development of 
neurogenic inflammation (Weglicki et al., 1994).  
 
Conclusion 
The current overview and additional data has highlighted the critical role that neurogenic 
inflammation plays in the secondary injury process following acute brain injury, with particular 
focus on TBI and ischaemic stroke. An increase in SP release appears to be a ubiquitous feature 
of TBI and critical to cellular outcome within the penumbral region following ischaemic stroke, 
as well as within those areas experiencing reperfusion after stroke. Neurogenic inflammation 
appears to exacerbate neuronal damage through a number of mechanisms including promoting 
BBB breakdown, with the subsequent development of vasogenic oedema, augmenting the 
inflammatory response and enhancing excitotoxicity. Preventing the actions of SP through use 
of an NK1 antagonist has been shown to be a promising therapeutic agent in experimental 
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Figure 1: Overview of neurogenic and classical inflammation following acute CNS 
injury. 
 
Figure 2: SP immunoreactivity following diffuse TBI of varying severity. Rats were injured 
using the Marmarou impact acceleration model as previously described (Carthew et al., 2012; 
Donkin et al., 2009) with a 450g brass weight released from a height of either 0.5, 1, 1.5 or 2m 
onto a metal helmet that was adhered centrally to the animal’s skull. 24h following injury, the 
brains were processed and then stained with SP (scale bar = 100µm; images are representative 
of n=3-4/group). Note the increased intensity of SP immunoreactivity (brown staining) with 
increasing severity of injury. 
 
Figure 3: Effect of an NK1 antagonist on motor outcome following fluid percussion 
induced TBI in rats. Following moderate fluid percussion injury (Faden et al., 1989), rats 
(n=6/group) were treated with 2.5mg/kg iv n-acetyl-L-trytophan (NAT) at 30 mins post-trauma 
and then assessed for motor outcome on the rotarod (Heath et al., 1999) daily for 7 days. Note 
that the NK1 antagonist significantly improved outcome (* = p < 0.05; mean ± SEM; repeated 
ANOVA followed by student Neuman-Keuls tests) when compared to vehicle (saline) treated 
controls. 
 
Figure 4: Therapeutic window for administration of an NK1 antagonist following 
ischaemic stroke. NK1 antagonist treatment (NAT; 25µmoles/kg iv) improved (A) motor 
outcome as assessed using a rotarod device when administered up to 8h following stroke and 
(B) sensory function as assessed using the bilateral asymmetry test (Turner et al., 2014) when 
administered up to 12h following MCA occlusion in the rat (n=6/group; mean ± SEM; * 
p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared to saline vehicle; repeated ANOVA 
followed by student Neuman-Keuls tests). 
 
Figure 5: Effects of an NK1 antagonist on motor outcome following mild to severe stroke. 
NK1 antagonist treatment (NAT; 25µmoles/kg in saline, iv) significantly improved motor 
function as assessed using the rotarod test when administred at 8h following (A) 60 min, (B) 
90mins or (C) 120 mins of MCA occlusion in the rat (n=6 /group; mean ± SEM; *p<0.05, ** 
p<0.01, *** p<0.001, **** p<0.0001 compared to shams; repeated ANOVA followed by 
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